<DOC>
	<DOCNO>NCT02436512</DOCNO>
	<brief_summary>The EAGLE study Phase 3 , open-label , multi-center , two-part , single-arm study GeNOsyl ( R ) delivery system ( ) evaluate inhale nitric oxide-induced vasodilation predict successful wean parenteral prostacyclin ( PGI ) subject World Health Organization ( WHO ) Group 1 pulmonary arterial hypertension ( PAH ) undergo medically necessary right heart catheterization ( RHC ) . All subject enrol study undergo attempt wean parenteral PGI per standard care .</brief_summary>
	<brief_title>Study Assess Acute Vasodilation Response Inhaled Nitric Oxide</brief_title>
	<detailed_description>This study divide 2 part : Pilot Phase follow Pivotal Phase . - The Pilot Phase enroll 20 subject . The information derive Pilot Phase evaluate safety , assess vasoreactivity test response rate . - Approximately 150 subject enrol Pivotal Phase study , gather data wean success parenteral PGI . The Investigator study staff involve wean patient management blind phase study vasoreactivity result .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>The subject subject 's legally authorize representative sign date Institutional Review Board ( IRB ) approve informed consent form prior initiation studyrelated activity . The subject diagnose PAH ( WHO Group 1 ) WHO Functional Class I II Screening . The subject document continuous PGI use ≥ 1 year Screening , without significant interruption ( i.e. , ≤ 2 day interruption ) without fail complete wean attempt . The subject candidate wean parenteral PGI therapy ( per Investigator judgment standard care ) . Exclusion Criteria The subject hypersensitivity allergy ingredient inhale nitric oxide clinically significant allergy ( clinical significance per Investigator judgment ) . The subject PCWP leave ventricular end diastolic pressure ( LVEDP ) ≥15 mmHg Baseline . The subject participate investigational product device study within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>